NAD+: Why It Is Not a Peptide and What the Research Covers

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

This article explains why NAD+ is catalogued next to peptides even though it is not one, what the molecule is chemically, how cells make and consume it, what the age-decline and precursor literature reports in human tissue, mice, and human volunteers, and why the compound is notoriously unstable in solution. It closes with what a certificate for a research lot of NAD+ should show, since several standard peptide lines do not apply.

NAD+ is a dinucleotide coenzyme, not a peptide

Nicotinamide adenine dinucleotide is two nucleotides joined through a pyrophosphate bridge: a nicotinamide riboside on one side and an adenosine on the other. Its formula is C21H27N7O14P2, its molecular weight about 663.4 daltons, its PubChem CID 5892, and its CAS number 53-84-9; older literature calls it nadide or coenzyme I. It contains no amino acids and no peptide bonds, so the vocabulary built around peptides, sequence, termini, net peptide content, peptidase sensitivity, does not apply. It sits in a research-peptide catalog for practical reasons: it is supplied as a lyophilized powder, stored cold, reconstituted in water, and tested with the same instruments. For the definition of what does count as a peptide, see what is a peptide; for another non-peptide that lives in the same catalog, see 5-Amino-1MQ.

The chemistry that makes NAD+ useful is the nicotinamide ring. The oxidized form, NAD+, carries a positive charge on the ring nitrogen and accepts a hydride ion at carbon 4 to become NADH; only the reduced form absorbs at 340 nanometers, the basis of most dehydrogenase assays. Houtkooper and colleagues, in a 2010 Endocrine Reviews paper, set out the second role that has driven the last two decades of interest: NAD+ is also a substrate, consumed rather than cycled, by three enzyme families, the sirtuin deacylases, the poly(ADP-ribose) polymerases, and the CD38 and CD157 cyclases. Each cleaves the glycosidic bond between nicotinamide and ribose, so every such reaction removes one NAD+ molecule from the pool.

How cells make NAD+: the salvage pathway and the precursor family

Mammalian cells build NAD+ by three routes, and the salvage route carries most of the flux. De novo synthesis starts from tryptophan and proceeds through the kynurenine pathway to quinolinic acid; the Preiss-Handler route starts from nicotinic acid; and the salvage route recycles the nicotinamide released by the consuming enzymes. In salvage, nicotinamide phosphoribosyltransferase (NAMPT) converts nicotinamide to nicotinamide mononucleotide (NMN), and the NMNAT enzymes adenylate NMN to NAD+. NAMPT is the rate-limiting step.

Bieganowski and Brenner added a fourth entry point in a 2004 Cell paper. Working in yeast, they showed that nicotinamide riboside (NR) is converted to NAD+ by a dedicated kinase family, the NRK enzymes, independently of the Preiss-Handler route, identified human homologs, and reported NR as a nutrient present in milk. That paper is the origin of the NR and NMN precursor literature. Covarrubias and colleagues' 2021 review in Nature Reviews Molecular Cell Biology gives the current map: NAD+ falls with age in rodents and humans across tissues, and the open questions are how much of this transfers to human physiology and whether restoring levels is safe.

A point that matters for cell-culture design is that NAD+ itself is a charged, 663-dalton molecule that does not pass freely through membranes. Gasparrini, Sorci, and Raffaelli, in a 2021 Cellular and Molecular Life Sciences review, catalog the ectoenzymes, CD38, CD157, CD73, and nucleotide pyrophosphatase/phosphodiesterase 1, that hydrolyze extracellular NAD+ into smaller pyridine metabolites that cells then take up and rebuild. NAD+ added to a medium is therefore largely disassembled outside the cell and resynthesized inside.

What the age-decline literature reports

The human tissue evidence comes from one well-cited study. Massudi and colleagues, in a 2012 PLoS One paper, measured NAD+, PARP activity, SIRT1 activity, and oxidative damage markers in pelvic skin samples from 49 people ranging from newborns to 77 years. NAD+ content fell with age in both sexes, with correlation coefficients of about -0.71 in males and -0.54 in females, while PARP activity rose with age in males and correlated inversely with tissue NAD+. It is cross-sectional and covers one tissue, but it is the direct human measurement most reviews cite.

Two mouse papers supply the mechanism. Gomes and colleagues, in a 2013 Cell paper, reported that aging mice lose mitochondrially encoded subunits of the oxidative phosphorylation system while nuclear-encoded subunits are preserved, traced this to a drop in nuclear NAD+ that allows HIF-1alpha to accumulate under normal oxygen (a pseudohypoxic state), and showed that raising NAD+ in old mice restored mitochondrial function to a youthful pattern in a SIRT1-dependent way. Camacho-Pereira and colleagues, in a 2016 Cell Metabolism paper, identified a consumer rather than a synthesis defect: CD38 expression and activity rise with age in mouse tissues, mice lacking CD38 are protected from the age-related NAD+ decline and the associated mitochondrial dysfunction, and CD38 turned out to be the main enzyme that degrades NMN in vivo.

Precursor studies in mice and in human volunteers

Almost all of the intervention literature uses precursors, NMN or NR, not NAD+ itself. Mills and colleagues, in a 2016 Cell Metabolism paper, supplied NMN in drinking water to regular-chow C57BL/6N mice for twelve months and measured less age-associated gain in body mass, higher energy expenditure and physical activity, better insulin sensitivity and plasma lipids, and preserved mitochondrial oxidative metabolism in skeletal muscle, with no obvious toxicity. De Picciotto and colleagues, in a 2016 Aging Cell paper, gave NMN to old mice and reported restored endothelium-dependent dilation of the carotid artery, lower aortic pulse-wave velocity, normalized superoxide production, and restored vascular SIRT1 activity.

Human pharmacokinetic studies have been done with NR. Trammell and colleagues, in a 2016 Nature Communications paper, showed that oral NR raised mouse liver NAD+ with kinetics superior to nicotinic acid or nicotinamide, that blood NAD+ in a single volunteer rose as much as 2.7-fold, and that in a small trial across three amounts the blood NAD+ metabolome rose in proportion; they also found that nicotinic acid adenine dinucleotide (NAAD) rises sharply and serves as a sensitive marker of repletion. Airhart and colleagues, in a 2017 PLoS One open-label study of eight healthy volunteers, measured a doubling of whole-blood NAD+ at steady state. Elhassan and colleagues, in a 2019 Cell Reports randomized crossover trial in twelve older men, found that three weeks of NR raised the skeletal-muscle NAD+ metabolome, lowered circulating inflammatory cytokines, and produced transcriptomic changes, but did not alter muscle mitochondrial bioenergetics.

None of these studies examined NAD+ as the supplied compound, and none of their results describe a research vial of the dinucleotide; they are reported here as literature context only.

Why NAD+ is unstable in solution

Lowry, Passonneau, and Rock, in a 1961 Journal of Biological Chemistry paper that is still the standard reference, established the asymmetry that governs all handling: the oxidized form, NAD+, is stable in acid but destroyed in alkali, whereas the reduced form, NADH, is stable in alkali but destroyed in acid. At neutral pH and room temperature, NAD+ degrades slowly by hydrolysis of the nicotinamide-ribose glycosidic bond, releasing nicotinamide and ADP-ribose, and by base-catalyzed ring reactions that accelerate as pH rises.

Two later studies add detail. Rover Júnior and colleagues, in a 1998 Analytical Biochemistry paper, followed cofactor solutions by UV-visible spectrophotometry in a factorial design and found that phosphate buffer accelerated loss relative to PIPES buffer, which they attributed to adduct formation between phosphate and the pyridine ring, with pH and temperature as the next most important factors. Hofmann and colleagues, in a 2010 Analytical and Bioanalytical Chemistry paper, used HPLC and high-resolution mass spectrometry to identify the thermal degradation products of the reduced cofactors and concluded that degradation in water is markedly faster than in the solid, with hydrolysis and oxidative ring opening as the main routes; the dry solid degraded significantly only above 95 degrees Celsius.

The laboratory rules follow directly. The lyophilized solid is the stable form and should be kept cold and dry, since the powder is hygroscopic. Solutions should be prepared fresh in water or a non-phosphate buffer, kept cold, and used promptly. How these rules play out across the three formats, vial, dissolving strip, and liquid spray, is covered in NAD+ in a vial, a strip, and a spray.

Regulatory status and what a certificate should show

NAD+ is not an approved drug in the United States. Its precursor niacin is approved by the FDA as a prescription product for lipid disorders, and nicotinamide is a vitamin; NR and NMN have been marketed as dietary-supplement ingredients, and the regulatory status of NMN in that category has been contested. None of that applies to a research lot of the dinucleotide, which is sold for in vitro work only. The broader list of approval statuses is in the FDA status reference table.

Because the molecule is not a peptide, a certificate reads differently. Identity by LC-MS should show the protonated ion near m/z 664.1 or the intact cation near m/z 663.1, not a sequence-derived mass. Purity by HPLC should be run with UV detection at 260 nanometers, and the chromatogram should be checked for the two characteristic contaminants, nicotinamide from hydrolysis and NADH from reduction, the latter also detectable at 340 nanometers. The net peptide content line is meaningless and should be replaced by an assay value in percent by mass and a Karl Fischer water content, since residual water in a hygroscopic solid changes the effective mass. The counter-ion, free acid or sodium salt, should be stated. Endotoxin and sterility lines apply only if the lot is filled as a sterile solid. US Prime Peptides lists NAD+ 500 mg, NAD+ 1000 mg, and an NAD+ liquid spray 500 mg with lot-matched certificates posted before purchase; what a standard panel cannot tell you is covered in what a certificate does not test for.

Frequently Asked Questions

Is NAD+ a peptide?

No. NAD+ is a dinucleotide: nicotinamide riboside and adenosine joined through a pyrophosphate bridge, formula C21H27N7O14P2, molecular weight about 663. It contains no amino acids and no peptide bonds.

Why does NAD+ degrade in solution?

The glycosidic bond between nicotinamide and ribose hydrolyzes in water, faster as pH and temperature rise, and phosphate buffers accelerate loss through adduct formation. The 1961 Lowry paper established that oxidized NAD+ is acid-stable and alkali-labile. The lyophilized solid is the stable form; solutions should be made fresh and kept cold.

Does NAD+ decline with age?

In the tissues that have been measured, yes. A 2012 study of human pelvic skin from 49 people found NAD+ content falling with age while PARP activity rose, and mouse studies attribute the decline to rising CD38 activity and to reduced nuclear NAD+ disrupting mitochondrial gene expression. Whether restoring levels changes outcomes in humans has not been established.

Is NAD+ an approved drug?

No. NAD+ is not an approved drug in the United States. Niacin is approved by the FDA as a prescription lipid product, nicotinamide is a vitamin, and NR and NMN have been sold as supplement ingredients, but a research lot of the dinucleotide is none of those and is supplied for in vitro use only.

Citations

1. Lowry OH, Passonneau JV, Rock MK. The stability of pyridine nucleotides. J Biol Chem. 1961;236:2756-2759. PMID 14466980
2. Rover Júnior L, Fernandes JC, de Oliveira Neto G, et al. Study of NADH stability using ultraviolet-visible spectrophotometric analysis and factorial design. Anal Biochem. 1998;260:50-55. PMID 9648652
3. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117:495-502. PMID 15137942
4. Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31:194-223. PMID 20007326
5. Hofmann D, Wirtz A, Santiago-Schübel B, Disko U, Pohl M. Structure elucidation of the thermal degradation products of the nucleotide cofactors NADH and NADPH by nano-ESI-FTICR-MS and HPLC-MS. Anal Bioanal Chem. 2010;398:2803-2811. PMID 20803196
6. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7:e42357. PMID 22848760
7. Gomes AP, Price NL, Ling AJ, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155:1624-1638. PMID 24360282
8. de Picciotto NE, Gano LB, Johnson LC, et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016;15:522-530. PMID 26970090
9. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23:1127-1139. PMID 27304511
10. Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PMID 27721479
11. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24:795-806. PMID 28068222
12. Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12:e0186459. PMID 29211728
13. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28:1717-1728. PMID 31412242
14. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119-141. PMID 33353981
15. Gasparrini M, Sorci L, Raffaelli N. Enzymology of extracellular NAD metabolism. Cell Mol Life Sci. 2021;78:3317-3331. PMID 33755743

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.